Page 86 - The clinical aspects and management of chronic migraine Judith Anne Pijpers
P. 86
84
Chapter 4
References
1. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455-464. doi:10.1038/nrneurol.2016.93
2. Schwedt TJ. Chronic migraine. Bmj. 2014;348(mar 24 5):g1416. doi:10.1136/bmj.g1416
3. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808. doi:10.1177/0333102413485658
4. Munksgaard SB, Bendtsen L, Jensen RH. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: a comparison of two consecutive treatment methods in an open-label design. Cephalalgia. 2012;32(11):834-844. doi:10.1177/0333102412451363
5. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9(4):391-401. doi:10.1016/S1474-4422(10)70008-9
6. Pijpers JA, Louter MA, De Bruin ME, et al. Detoxification in medication-overuse headache, a retrospective controlled follow-up study: Does care by a headache nurse lead to cure? Cephalalgia. 2016;36(2):122-130. doi:10.1177/0333102415583146
7. Chiang C-C, Schwedt TJ, Wang S-J, Dodick DW. Treatment of medication-overuse headache: A systematic review. Cephalalgia. 2016;36(4):371-386. doi:10.1177/0333102415593088
8. Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L. Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial. Cephalalgia. 2018;38(2):225-236. doi:10.1177/0333102417737779
9. Zeeberg, Olesen J, Jensen R. Probable medication-overuse headache: the effect o a 2-month drug- free period. Neurology. 2006;66(12):1894-1898. doi:10.1212/01.wnl.0000217914.30994.bd
10. Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication- overuse headache: Evaluation in a multicentric , multinational study. 2014;34(9):645-655. doi:10.1177/0333102414521508
11. Rossi P, Faroni J V., Nappi G. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol. 2011;18(3):396-401. doi:10.1111/j.1468-1331.2010.03157.x
12. Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache: A prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26(9):1097-1105. doi:10.1111/j.1468-2982.2006.01175.x
13. Rossi P, Faroni JV, Tassorelli C, Nappi G. Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain. 2013;14(1):10. doi:10.1186/1129-2377-14-10
14. Zeeberg, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006;26(10):1192-1198. doi:10.1111/j.1468- 2982.2006.01190.x
15. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001;57(9):1694– 1698. doi:10.1212/WNL.57.9.1694
16. Diener H-C. Detoxification for medication overuse headache is not necessary. Cephalalgia. 2012;32(5):423-427. doi:10.1177/0333102411425867
17. Olesen J. Detoxification for medication overuse headache is the primary task. Cephalalgia. 2012;32(5):420-422. doi:10.1177/0333102411431309
18. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017;69(2):200-235. doi:10.1124/pr.116.012658
19. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-1826. doi:10.1212/WNL.0000000000002560
